Literature DB >> 7248160

Elevated levels of prolactin in nulliparous women.

M C Yu, V R Gerkins, B E Henderson, J B Brown, M C Pike.   

Abstract

Follicular-phase (Day 11) plasma prolactin, and plasma and urinary oestrogen levels of 70 nulliparous nuns were compared with those of 80 of their sisters, of whom 62 were parous. The nuns and their nulliparous sisters did not differ significantly in their prolactin and oestrogen levels. No differences in plasma oestrogens or urinary oestriol ratio were found between the parous and the nulliparous women. However, the mean prolactin level of the nuns and their nulliparous sisters was 35% higher than that of the parous women in the sample taken approximately 1 3/4 h after rising (p less than 0.0005), and 24% higher (P less then 0.01) in the 2nd sample taken 2 h later. The elevation was independent of age, weight, and age at menarché. Age at first full-term pregnancy, at least up to the age of 30, and second or subsequent full-term pregnancies had no further effect on prolactin level. This study suggests that the effect of early first full-term pregnancy in lowering breast cancer risk may be mediated, at least in part, by permanently lowering the level of circulating prolactin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248160      PMCID: PMC2010727          DOI: 10.1038/bjc.1981.121

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  The influence of exogenous estrogen on the circadian periodicity of circulating prolactin in women.

Authors:  M Vekemans; C Robyn
Journal:  J Clin Endocrinol Metab       Date:  1975-05       Impact factor: 5.958

2.  Mutation selection and the natural history of cancer.

Authors:  J Cairns
Journal:  Nature       Date:  1975-05-15       Impact factor: 49.962

3.  Comparison of urinary and plasma hormone levels in daughters of breast cancer patients and controls.

Authors:  M C Pike; J T Casagrande; J B Brown; V Gerkins; B E Henderson
Journal:  J Natl Cancer Inst       Date:  1977-11       Impact factor: 13.506

Review 4.  Etiology of human breast cancer: a review.

Authors:  B MacMahon; P Cole; J Brown
Journal:  J Natl Cancer Inst       Date:  1973-01       Impact factor: 13.506

5.  Further observations on the Kober colour and Ittrich fluorescence reactions in the measurement of oestriol, oestrone and oestradiol.

Authors:  J B Brown; C Macnaughtan; M A Smith; B Smyth
Journal:  J Endocrinol       Date:  1968-02       Impact factor: 4.286

6.  Disordered nocturnal prolactin regulation in women with breast cancer.

Authors:  W B Malarkey; L L Schroeder; V C Stevens; A G James; R R Lanese
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

7.  Influence of age on serum prolactin levels in women and men.

Authors:  M Vekemans; C Robyn
Journal:  Br Med J       Date:  1975-12-27

8.  Prolactin levels in populations at risk for breast cancer.

Authors:  P Hill; E L Wynder; H Kumar; P Helman; G Rona; K Kuno
Journal:  Cancer Res       Date:  1976-11       Impact factor: 12.701

9.  Oestrogen profiles of parous and nulliparous women.

Authors:  P Cole; B MacMahon; J B Brown
Journal:  Lancet       Date:  1976-09-18       Impact factor: 79.321

10.  Serum oestradiol-17 beta in normal women.

Authors:  P C England; L G Skinner; K M Cottrell; R A Sellwood
Journal:  Br J Cancer       Date:  1974-06       Impact factor: 7.640

View more
  16 in total

Review 1.  The international variation in breast cancer rates: an epidemiological assessment.

Authors:  B E Henderson; L Bernstein
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

2.  Age at menarche and estrogen concentrations of adult women.

Authors:  L Bernstein; M C Pike; R K Ross; B E Henderson
Journal:  Cancer Causes Control       Date:  1991-07       Impact factor: 2.506

3.  Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.

Authors:  Patricia Castillo; Omonigho Aisagbonhi; Cheryl C Saenz; Wael M ElShamy
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

4.  Decreasing hormonal promotion is key to breast cancer prevention.

Authors:  Lakshmanaswamy Rajkumar; Amy Canada; David Esparza; Katherine Collins; Enrique Moreno; Huyen Duong
Journal:  Endocrine       Date:  2009-02-12       Impact factor: 3.633

5.  Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Megan S Rice; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-14       Impact factor: 4.254

6.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

7.  Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development, and social gradients, including black/white differences, in breast cancer incidence.

Authors:  N Krieger
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

8.  Season of tumour detection influences factors predicting survival of patients with breast cancer.

Authors:  B H Mason; I M Holdaway; A W Stewart; L M Neave; R G Kay
Journal:  Breast Cancer Res Treat       Date:  1990-01       Impact factor: 4.872

9.  Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.

Authors:  Maria Hietala; Håkan Olsson; Helena Jernström
Journal:  Fam Cancer       Date:  2007-12-15       Impact factor: 2.375

10.  Parity is associated with axillary nodal involvement in operable breast cancer.

Authors:  R K Orr; K M Fraher
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.